Methadone: applied pharmacology and use as adjunctive treatment in chronic pain

R Brown, C Kraus, M Fleming, S Reddy

This article reviews the unique pharmacological properties of methadone and outlines its appropriate clinical application, with focus upon its use in the treatment of chronic pain. Although methadone is most widely known for its use in the treatment of opioid dependence, methadone also provides effective analgesia. Patients who experience inadequate pain relief or intolerable side effects with other opioids or who suffer from neuropathic pain may benefit from a transition to methadone as their analgesic agent. Adverse effects, particularly respiratory depression and death, make a fundamental knowledge of methadone’s pharmacological properties essential to the provider considering methadone as analgesic therapy for a patient with chronic pain.

Methadone is a synthetic opioid medication best known for its use in the treatment of opioid dependence. Methadone is also an effective analgesic agent, potentially with increased efficacy in the setting of neuropathic pain. Patients experiencing inadequate analgesia or adverse effects while on other opioids may also benefit from a transition to methadone. Additionally, unique pharmacological properties make methadone a useful addition to the care provider’s arsenal of prescription analgesic agents.

Methadone’s excellent oral bioavailability and mucosal absorption, effectiveness as an analgesic agent, low cost, long half life, and availability in oral, parenteral, and suppository forms make it an excellent alternative for the treatment of both cancer and non-cancer pain. Medication interactions and the potential for serious adverse effects (particularly central apnoea and death, which have received recent attention in the popular press) make an understanding of methadone’s pharmacological profile essential to the prescribing provider.

Many individuals participating in methadone maintenance treatment for opioid dependence seek medical care in the community outside of their addiction treatment facility. An understanding of potential adverse effects and medication interactions is important when caring for this population as well, so that the provider can avert untoward events resulting from medication interactions.

In this article, we discuss the pharmacology of methadone and briefly comment upon its use in the treatment of opioid dependence and withdrawal. We then focus upon an approach to the prescription of methadone for the treatment of chronic pain conditions. Finally, we discuss the adverse effects of and potential drug interactions with methadone which may occur with usual clinical use.

PHARMACOLOGY

Methadone occurs in R-enanomorphic and S-enanomorphic forms, with essentially all of its activity due to activity of R-methadone. Methadone exerts its activity through binding to and activating µ opioid receptors centrally and in the periphery. This activity produces the effects common to all µ opioid agonists: analgesia, euphoria, constipation, sedation, respiratory depression, nausea, and miosis. Additionally, methadone antagonises N-methyl-D-aspartate receptors, which may increase its effectiveness in the treatment of neuropathic pain compared with other opioids.

Pharmacokinetics

Methadone is a fat soluble drug which is rapidly absorbed after oral administration. Time to peak concentration, however, varies from one to five hours. Methadone induced slowing of gastric emptying may account for longer time to peak concentration in chronic users. Oral bioavailability of tablets is approximately 60–70%, but wide variation among patients exists. The analgesic effect of a dose begins within 30 to 60 minutes after administration and generally lasts for four to six hours.

Methadone is highly bound to plasma proteins. In particular, α1-acid glycoprotein is important, because disease states, like cancer, may induce a rise in the concentration of this protein and, as a result, affect the concentration of free methadone. Certain drugs may influence α1-acid glycoprotein concentrations and, in turn, methadone concentrations. Methadone may be displaced from plasma proteins by drugs like propranolol, certain phenothiazines, and imipramine. Other drugs may decrease plasma protein and, theoretically, increase free methadone levels. Examples of such drugs are carmustine and mechlorethamine. Finally, drugs may also selectively compete for protein binding sites, resulting in situations where their own free levels might increase. The tricylic antidepressants, progesterone, and lidocaïne are a few examples. Although animal data suggest that dose adjustments based on protein binding may be necessary, there are no data in humans to suggest these interactions are clinically significant.

See end of article for authors’ affiliations

Correspondence to:
Dr Randall Brown
University of Wisconsin
Department of Family Medicine, 777 S Mills St
Madison, WI 53715, USA;
rjbrown@fammed.wisc.edu

Submitted 14 April 2004
Accepted 10 May 2004

www.postgradmedj.com
Methadone is widely distributed to tissue, and, with
continuous use, tissue levels may exceed levels in plasma.
This extensive protein and tissue binding is responsible for
the long plasma half life of the drug, particularly with
continuous use. Methadone metabolism to inactive forms is the
principle means of elimination. Less than 10% of an oral dose is
extracted by the liver during first pass. The drug is
metabolised both by the liver and by intestinal CYP 3A4
and, to a lesser extent, by CYP 2D6. Some of the variability of
enzyme activity in different people likely accounts for the
large differences in clearance and half life of methadone seen
within a population. For example, due to a polymorph of
CYP 2D6, a subset of the white population, less than 10%, are
considered to be poor metabolisers of methadone. Estimates
of methadone half life vary from 15 to 55 hours. In addition
to metabolic inactivation, parent drug and metabolites are
also eliminated in the faeces and urine. Age does not appear to have a large influence on clearance and
generally no change in dose is required for persons over
age 65 years. For patients with impaired renal function,
methadone clearance via faeces will increase and no dose
adjustment is necessary. For patients with end stage renal
disease, some experts suggest a 50% reduction in methadone
dosing. Because methadone is highly protein bound, little is
expected to be removed from the plasma with dialysis.
Patients with chronic, stable liver diseases may be able to
 tolerate usual methadone maintenance doses. For patients
with acute hepatitis and elevated liver enzymes, higher doses
of methadone may be required.

No relationship has been established between plasma
centration and analgesic effect. For the treatment of
chronic pain, treatment should be titrated to clinical effect
rather than a drug level.

CLINICAL APPLICATIONS
Methadone for opioid dependence
Since the enactment of the Narcotic Addicts Treatment Act in
1973, methadone prescription in the United States for opioid
dependence or opioid withdrawal has been (and continues to
be) legal only in the setting of a federally licensed methadone
maintenance facility. Resources for the care of the health issues
unrelated to substance abuse are often limited in these
facilities. Methadone maintained individuals, therefore,
frequently seek medical care from community providers.

Over 150,000 opioid dependent individuals are enrolled in
methadone treatment centres in the United States. The
United States Office of National Drug Control Policy
estimates that these services reach one in 10 to one in eight
actively opioid dependent individuals in the United States.

Methadone maintenance treatment has been shown to
decrease use of heroin and other drugs; reduce the acquisi-
tion and transmission of HIV; hepatitis B, and hepatitis
C; reduce criminal behaviour; and has been shown to be a
cost effective treatment for opioid dependence. Most of the
benefits of methadone maintenance have been shown to be
related to methadone dose and to duration of treat-
ment.

Methadone for chronic pain
Federal and state regulations restricting the use of metha-
done in the setting of opioid dependence and withdrawal to
spatially licensed facilities do not apply to the prescription of
methadone for chronic pain. Therefore, the care provider may
consider the use of methadone as an analgesic agent for the
treatment of chronic pain.

In addition to being effective treatment for opioid
dependence, methadone provides effective analgesia with
several unique properties. Patients experiencing adverse
effects (constipation, euphoria, nausea/vomiting) or inade-
quate analgesia with other prescribed opioids may benefit
from a transition to methadone. Additionally, methadone
often provides analgesia superior to other opioids in the
setting of neuropathic pain syndromes. Furthermore, a
reduced level of tolerance to analgesic effects and less
constipation has been reported for methadone as opposed to
other opioids.

Given the short duration of analgesia (4–6 hours) relative
to methadone’s half life, the use of methadone as an
analgesic agent requires a more frequent dosing regimen
than the daily dosing used for the treatment of opioid
dependence. Usual analgesic treatment regimens with
methadone require dosing every eight to 12 hours. The long
half life of methadone in the setting of more frequent dosing
creates the potential for drug accumulation and adverse
effects. Many protocols for a transition to methadone from
other opioid analgesics have been put forward in the
literature. These methods are of two basic types: (1) a
rapid transition in which the previously prescribed opioid
is completely discontinued with institution of methadone
analgesic therapy, and (2) a slow transition in which the
previously prescribed opioid is tapered in conjunction with
titration of methadone dosing. Equianalgesic doses of the
most commonly prescribed opioids are provided in table 1.

Table 1

<table>
<thead>
<tr>
<th>Drug</th>
<th>Equianalgesic doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine</td>
<td>180–200 mg</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>25 μg transdermal</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>30 mg</td>
</tr>
<tr>
<td>Morphine</td>
<td>30–60 mg oral</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>30 mg</td>
</tr>
</tbody>
</table>

* Methadone conversion is not included due to varying
conversion ratios at varying prior doses of other opioids.
See boxes 1 and 2 for appropriate conversion to methadone
based upon morphine milligram equivalents.

Though not generally a first line agent, methadone may be
considered early on in the treatment of neuropathic pain and/or
in situations where cost issues are compelling. This
situation mandates caution because, in the opioid naïve
patient, methadone may precipitate respiratory arrest. A
history of sleep apnoea, severe asthma or respiratory failure,
right heart failure, morbid obesity, or the concurrent use or
abuse of sedative drugs (for example, alcohol, muscle
relaxants) increase the risk of respiratory depression or arrest
with methadone. The first visit with the care provider should,
therefore, include a detailed medical history to screen for
these high risk situations. A methadone regimen for chronic
pain in the opioid naïve patient may then begin with a low
dose (5 mg or less twice daily) and be gradually (an
additional 5 mg daily every 72 hours) titrated upward to
pain relief. Total daily doses exceeding 120 mg are rarely
required to provide adequate 24 hour analgesia. As needed
doses of short acting analgesics, such as oxycodone, hydro-
codone, or short acting morphine preparations, may be
considered for the treatment of breakthrough pain.

An optimal concentration of methadone for maintenance
therapy for opioid dependence is considered to be 400 μg/l,
although in some studies, designed to determine an effective
concentration, a threshold was not found. On the other hand,
some patients will have a reasonable clinical response with
lower serum concentrations and other factors such as
receptor sensitivity, social support, and psychological issues
may also play a part. Therefore, therapeutic drug monitoring
The use of the previous opioid is stopped and replaced by a fixed dose of methadone. A patient who was receiving 300 mg or less of morphine milligram equivalents daily would have the dose replaced at a ratio of 10 mg morphine: 1 mg methadone. A patient receiving greater than 300 mg of morphine milligram equivalents daily would receive a fixed dose of 30 mg methadone. This dose is then used at intervals of not less than three hours as needed for analgesia.

On day 6, the amount of methadone administered over three hours as needed for analgesia.

Methadone requirements should be expected to decline during days 2 and 3 and reach steady state on days 4–5.

is not recommended routinely for all patients receiving methadone maintenance. No relationship has been established between plasma concentration and analgesic effect.

For the treatment of chronic pain, therefore, treatment should be titrated to clinical effect rather than a drug level.

CESSATION/TAPER OF METHADONE

Should cessation of methadone treatment be indicated, gradual tapering will minimise withdrawal symptoms. The taper generally should not exceed 1 mg/day. A 5 mg/week taper is convenient given methadone’s availability in 5 mg and 10 mg tablet forms.

Aching muscles and joints, insomnia, nausea, and mood changes may indicate opioid withdrawal. If the patient begins to experience opioid withdrawal effects, symptomatic treatments on an as-needed basis may assist in the management of a continued taper if necessary. Clonidine or a β-blocker may alleviate sympathomimetic symptoms (tachycardia, lacrimation, stuffy nose, sweats). These medications

<table>
<thead>
<tr>
<th>Table 2 Drug interactions associated with enhanced methadone effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmacokinetic effects</strong></td>
</tr>
<tr>
<td>Antibiotics</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
</tr>
<tr>
<td>Fluconazole</td>
</tr>
<tr>
<td>Antidepressants</td>
</tr>
<tr>
<td>Fluoxetine</td>
</tr>
<tr>
<td>Fluvoxamine</td>
</tr>
<tr>
<td>Paroxetine</td>
</tr>
<tr>
<td>Sertraline</td>
</tr>
<tr>
<td>Adapted with permission from Eap CB, Buclin T, Baumann P. Interindividual variability of clinical pharmacokinetics of methadone. Clin Pharmacokinet 2002; 41:1153-93, AUC, area under the curve.</td>
</tr>
</tbody>
</table>
may also alleviate some of the subjective irritability common in opioid withdrawal. Prochlorperazine or promethazine assist in the management of nausea and vomiting. Loperamide will alleviate diarrhoea. Dicyclomine calms abdominal cramping; and a limited supply of a benzodiazepine such as lorazepam, might be considered to assist in the control of insomnia and irritability/anxiety.

**SIDE EFFECTS OF METHADONE**

Familiarity with the side effect profile of methadone will assist the practitioner in the appropriate titration of a methadone regimen, will obviate the unnecessary laboratory investigation of signs and symptoms known to be common medication side effects, and may assist the practitioner in the management of these side effects.

Methadone acts upon central opioid receptors, as do the other opioid drugs. This action may reduce hypercapnoeic and hypoxic ventilatory drives resulting in respiratory depression. The most severe potential consequence of this effect is central apnoea. Many cases of mortality due to this effect have been reported. In most situations, medication interactions were missed, medical risk factors ignored, or doses increased too quickly. Methadone toxicity can also result from inadequately spaced dosage regimens (dosing more frequently than every eight hours) due to the drug’s long half life and consequent drug accumulation. Careful

<table>
<thead>
<tr>
<th>Table 3 Drug interactions associated with diminished methadone effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antivirals/nucleoside reverse transcriptase inhibitors</strong></td>
</tr>
<tr>
<td><strong>Efavirenz</strong></td>
</tr>
<tr>
<td><strong>Nevirapine</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Antivirals/protease inhibitors</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nelfinavir</strong></td>
</tr>
<tr>
<td><strong>Ritonavir/ saquinavir</strong></td>
</tr>
</tbody>
</table>

Adapted with permission from Eap CB, Buclin T, Baumann P. Interindividual variability of clinical pharmacokinetics of methadone. Clin Pharmacokinet 2002;41:1153–93. AUC, area under the curve.
dose titration, a thorough history for medical risk factors, and cognisance of medication interactions should avert this potentially catastrophic effect.

Due to central opioid receptor activation, somnolence is quite common during the first weeks of treatment before tolerance to this drug effect is gained. Methadone may also interfere with rapid eye movement sleep and sleep stages 3 and 4. When these changes persist during chronic treatment, insomnia may occur. Patients experiencing this side effect have lower sleep efficiency, less rapid eye movement, and less slow wave sleep accompanied by sleep disordered breathing. Additionally they spend more time in sleep stage 2.19

Methadone maintenance patients may also experience subjective cognitive slowing. Objective, controlled data on this phenomenon are scarce. Tolerance would be expected to this side effect as has been demonstrated with the chronic use of other opioid medications. A European study examining the cognitive effects of chronic methadone therapy concluded that methadone treatment was not, in itself, predictive of impairment in cognitive psychomotor skills; inferior performance on tests was more strongly related to sociodemographic factors.24 A second study demonstrated that psychophysical performances and driving aptitude are not significantly related to methadone dose.34

Weight gain is a commonly reported side effect among patients on methadone maintenance. The precise aetiology is unclear but may involve appetite increase and/or non-cardiogenic peripheral oedema. Previous studies have indicated an onset of weight gain three to six months after initiation of methadone maintenance treatment or after a sharp dosage increase.32 35

Sexual dysfunction is also a common complaint of individuals on chronic methadone. In men, orgasm dysfunction and a decrease in libido are the most common concerns. Spermatic dysmotility has also been described.36 37 Whether or not fertility is adversely affected has yet to be firmly established. Several studies that indicate subnormal levels of plasma testosterone in men maintained on methadone may account for these side effects, though a dose effect relationship has yet to be discovered.38 44 Women may experience dysfunction of libido as well as oligomenorrhea or amenorrhea.43 The aetiology of and potential treatments for these effects are unclear.

Up to 65% of patients report constipation as a direct effect of methadone.45 Tolerance to this peripheral opioid effect may not develop, often necessitating a scheduled bowel regimen during treatment with methadone.45

**DRUG INTERACTIONS WITH METHADONE**

There are many potential drug interactions with methadone. However, it is difficult to study drug interactions because methadone has a long half life, and time to steady state concentration after a change due to a drug interaction may require up to 10 days. Many of the drug interactions cited in the literature have not been rigorously investigated.46 In addition, even though statistically significant change in methadone concentration may occur as a result of a drug-drug interaction, the clinical outcome may not be significant, since methadone has such a wide therapeutic window, and because methadone’s half life varies significantly between individuals.44 In the setting of a potential drug interaction, therefore, it is reasonable to institute a dosing regimen as described in tables 2 or 3, and monitor the patient closely for signs of supratherapeutic dosing (sedation, euphoria).

Drug interactions with methadone most commonly occur due to inhibition or induction of liver enzymes. Although drugs like older macrolide antibiotics (troleandomycin), ketoconazole, and diazepam are able to inhibit CYP3A4 metabolism of methadone to its inactive metabolite by up to 80% in vitro, many of these agents do not exhibit the same degree of inhibition in vivo.47 A summary of medications associated with increased concentrations of methadone are found in table 2.44 50

Drugs which induce enzyme systems responsible for methadone metabolism may result in lowering of methadone levels. It is thought that chronic abuse of alcohol may increase liver enzymes and reduce methadone levels.49 51 Seizure medications like phenytoin, phenobarbital, and carbamazepine are classic examples of CYP3A4 enzyme inducers that may lower methadone concentrations.52 Of the antibiotics, rifampin has been shown to interfere with methadone. Of the antiviral medications used for the treatment of HIV, the non-nucleoside reverse transcriptase inhibitors increase the metabolism of methadone. Drug interactions resulting in lowered methadone concentrations can be found in table 3.52 53–60

Methadone levels may be affected by competition for enzyme metabolism. For example, some feel that binge drinking of alcohol may prevent appropriate metabolism of methadone, temporarily increasing concentrations.53 One example of preferential metabolism of methadone is its interaction with zidovudine, where increased zidovudine levels have been described.53 On the other hand, methadone appears to decrease the concentration of stavudine and didanosine by apparently decreasing their absorption.54 Finally, both alcohol and benzodiazepines have been associated with increased risk for respiratory depression in patients using opioids.14

**CONCLUSION**

In summary, methadone has important therapeutic applications beyond methadone maintenance for opioid dependence. It is a viable choice for patients with neuropathic pain, for pain resistant to treatment with other opioid analgesics, and for situations where dose limiting side effects occur from other opioid agents. Practitioners who prescribe methadone need to be familiar with its unique pharmacokinetic profile, side effects, and potential drug interactions to ensure safe, effective use of this agent.

**Authors’ affiliations**

R Brown, University of Wisconsin Department of Family Medicine and Department of Population Health Sciences, and Madison Health Services Methadone Treatment Facility, Madison, Wisconsin, USA

C Kraus, University of Wisconsin Department of Pharmacy, Madison, Wisconsin, USA

M Fleming, University of Wisconsin Department of Family Medicine, Madison, Wisconsin, USA

S Reddy, University of Wisconsin Medical School, Madison, Wisconsin, USA

**REFERENCES**


Methadone and chronic pain

13 Press A. Methadone overdose deaths on rise in MD. The State 7 January 2004 (section 1).